Last reviewed · How we verify
CYT004-MelQbG10
At a glance
| Generic name | CYT004-MelQbG10 |
|---|---|
| Sponsor | Cytos Biotechnology AG |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients (PHASE2)
- Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients (PHASE1, PHASE2)
- Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients (PHASE1, PHASE2)
- Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYT004-MelQbG10 CI brief — competitive landscape report
- CYT004-MelQbG10 updates RSS · CI watch RSS
- Cytos Biotechnology AG portfolio CI